Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Sanofi eyes successors for CEO Olivier Brandicourt
Monday, March 18, 2019
Sanofi is working on a succession plan for CEO Olivier Brandicourt, who'll hit mandatory retirement age in 2021.
Buoyed by Dupixent, Sanofi expects a brighter 2019
Thursday, February 7, 2019
After a strong fourth quarter, Sanofi expects further growth in 2019.
Cablivi is Sanofi’s first approval from Ablynx buyout
Wednesday, February 6, 2019
Sanofi just won FDA approval for Cablivi, acquired in its $4.5 billion Ablynx deal and expected to peak at $500 million in sales.
Dupixent and vaccines bring Sanofi back to growth
Wednesday, October 31, 2018
Dupixent grew sales by 28% sequentially at constant currencies, to €225 million, and that doesn't even count a recent major approval in asthma.
Sanofi’s first Ablynx drug Cablivi wins EU approval
Tuesday, September 4, 2018
Cablivi is the first Ablynx nanobody drug to win approval, and analysts have predicted peak sales of $500 million.
Sanofi’s first product from the Ablynx deal wins CHMP backing
Friday, June 29, 2018
Analysts previously predicted Cablivi (caplacizumab) could be the standard of care for aTTP, with peak global sales at $500 million.